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Abstract
Many life-cycle processes in parasites are regulated by protein phosphorylation. Hence, disruption 
of essential protein kinase function has been explored for therapy of parasitic diseases. However, 
the difficulty of inhibiting parasite protein kinases to the exclusion of host orthologues poses a 
practical challenge. A possible path around this difficulty is the use of bumped kinase inhibitors 
for targeting calcium dependent protein kinases that contain atypically small gatekeeper residues 
and are crucial for pathogenic apicomplexan parasites’ survival and proliferation. In this review, 
we review efficacy against the kinase target, the parasite growth in vitro, and in animal infection 
models, as well as the relevant pharmacokinetic and safety parameters of bumped-kinase 
inhibitors.
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1. Introduction
Protein kinase inhibitors have been sought for therapy of parasitic diseases, but the challenge 
of specific inhibition of parasite kinases versus mammalian kinases has limited their 
practical application. Bumped-kinase inhibitors (BKIs) were originally generated in Prof. 
Kevan Shokat’s laboratory to build specificity into protein kinase inhibitors that compete 
with ATP for the kinase active site (Bishop, et al., 1998, Bishop and Shokat, 1999) The 
“bump” on BKIs precludes their binding to almost all mammalian kinases, since these have 
a bulky gatekeeper residue in the ATP-binding pocket (see Fig. 1, below). Dr. Shokat’s 
group pioneered the use of BKIs in genetically-altered mammalian kinases, in which the 
bulky gatekeeper residue was mutated to glycine or alanine, rendering the mutant kinase 
susceptible to BKIs (Bishop, et al., 2000, Liu, et al., 1999) If the mutant protein kinase was 
active, the mutation could be introduced into the corresponding gene in mice, allowing the 
function of that kinase to be probed anytime during the life of the mice by inhibiting that 
kinase specifically with BKIs. BKIs had no discernable effects on wild-type mice in control 
experiments, providing evidence that these compounds as a class have low activity against 
mammalian kinases and hence low toxicity.
We and Dr. Hui’s group determined the structure of Toxoplasma gondii and 
Cryptosporidium parvum calcium-dependent protein kinase 1 (CDPK1) and immediately 
noticed that these parasite proteins contain a naturally occurring glycine gatekeeper residue 
in the ATP binding site (Ojo, et al., 2010, Wernimont, et al., 2010). We reasoned that this 
active site should therefore be sensitive to BKI inhibition and found that to be the case 
experimentally. Given the safety and specificity of BKIs demonstrated by Shokat’s group, 
we embarked on a medicinal chemistry project to optimize BKIs for use against parasites 
that have CDPKs, primarily apicomplexans. This review describes progress in this area.
2. Structural Basis of Cross-Parasite CDPK inhibition by BKIs
CDPKs have no closely related orthologs in vertebrates, but the CDPK kinase domain is 
similar in sequence and structure to other members of the large family of serine threonine 
kinases. As with many protein kinases, CDPKs have conformationally distinct active and 
inactive states that differ in their competence to bind to and act on their protein substrates. 
CDPK activity is not regulated through phosphorylation or interaction with a partner protein. 
Instead, regulation is accomplished via a radical reorganization of the calcium-binding 
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domain such that in the Ca-bound active state, substrate proteins have unobstructed access to 
the face of the CDPK containing the active site, while in the inactive state, access to this face 
of the protein is occluded (Ojo, et al., 2010, Wernimont, et al., 2010). The internal 
conformation of the active site pocket is unchanged between the active and inactive state. 
Even the “inactive” state is catalytically competent to phosphorylate small peptide 
substrates, and crystal structures show that the binding pose of ATP, ATP analogs, and ATP-
competitive inhibitors is maintained in both conformations (Murphy, et al., 2010, 
Wernimont, et al., 2010). Thus, both the active and inactive states of CDPKs are targeted by 
the BKIs discussed here.
The overall ATP binding pocket comprises three areas necessarily shared by all kinases: a 
region adjacent to the ATP β and 7gamma; phosphates containing the catalytic residues, a 
relatively hydrophilic pocket that accommodates the ATP ribose moiety, and a relatively 
hydrophobic pocket that accommodates the ATP purine group. Given this set of necessarily 
shared features, how is it possible to systematically design highly selective ATP-competitive 
compounds that potently inhibit target CDPKs in apicomplexan parasites while showing 
weak or no inhibition of mammalian kinases? The first key is a difference in the 
hydrophobic pocket that accommodates the ATP purine group. In a typical kinase the 
accessible volume of this pocket is limited by the side chain of a particular residue, the 
“gatekeeper” residue, whose position in the active site is strongly conserved (Zuccotto, et al., 
2010). The surface of the binding site formed by this gatekeeper sidechain is near atom N7 
of the ATP purine group and in a typical kinase prevents recognition of ATP analogs that 
have been chemically modified by the addition of a bulky group, colloquially called a 
“bump”, at this position. Substitution of a small amino acid (i.e., glycine, alanine, or serine) 
at the gatekeeper position removes this restriction, resulting in an enlarged hydrophobic 
pocket that can accommodate ATP analogs with such a bump. As noted above, BKIs were 
originally developed to exploit engineered large to small gatekeeper substitutions to create 
highly specific biological probes of kinase function (Bishop, et al., 2001, Bishop, et al., 
2000). Because small gatekeepers are universally rare in wild type mammalian kinases, 
pairing the introduction of an engineered sensitive kinase with a suitable bumped ATP 
analog or inhibitor constitutes a highly selective probe for that specific kinase (Zhang, et al., 
2005).
Various CDPK family members in apicomplexan parasites naturally possess a small 
gatekeeper residue. CDPK1 homologs from Toxoplasma gondii, Cryptosporidium parvum, 
Neospora caninum, and Sarcocystis neurona contain a glycine gatekeeper. CDPK4 from 
Plasmodium falciparum contains a serine. Previously characterized BKIs such as the 
pyrazolopyrimidines (PP) (Liu, et al., 1999) presented an obvious starting point for 
optimization of inhibitors highly selective for the target parasite enzymes over most host 
kinases (Johnson, et al., 2012, Lourido, et al., 2013, Murphy, et al., 2010). Human kinases 
containing a threonine gatekeeper, the next smallest amino acid, were thought to account for 
the initially imperfect BKI selectivity. Crystallographic comparison of BKIs bound to 
CDPK1 and to the representative threonine gatekeeper human kinase SRC showed that it is 
possible to increase selectivity by exploiting differences among kinases in the relative 
orientation of the ribose binding pocket (Larson, et al., 2012). This led to an optimization 
strategy that explored simultaneous substitution at two positions in the starting PP scaffold. 
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Substituents at the R1 position, the BKI “bump”, strongly reduce acceptance of gatekeepers 
larger than threonine; substituents at the R2 position extend into the ribose pocket and 
further restrict acceptance by threonine gatekeeper kinases.
The geometric presentation of the R1 and R2 groups characterized for the original PP 
scaffold is preserved by analogous substitutions onto an alternative 5-aminopyrazole-4-
carboxamide (AC) scaffold (Huang, et al., 2015, Zhang, et al., 2014). Thus both scaffolds 
exploit the same two primary determinants of CDPK1-specific inhibition (Fig. 1). The 
pharmacological properties of compounds based the two scaffolds differ, however. Both 
scaffolds are represented in the set of compounds discussed below that have shown the most 
promise in animal tests. Two other BKI scaffolds (Fig. 2) that do not preserve this precise 
geometry of presenting substituents have also been explored to target apicomplexan CDPKs, 
imidazopyridazines to target PfCDPK1 (Chapman, et al., 2013, Chapman, et al., 2014, 
Green, et al., 2016), and benzoylbenzimidazoles to target TgCDPK1 and CpCDPK1 (Zhang, 
et al., 2012).
Joint optimization of the R1 and R2 substituents has led to inhibitors that are >200-fold 
more active in vitro against CDPKs than against a panel of 80 to 240 human kinases 
(Vidadala, et al., 2016, Zhang, et al., 2014). This selective difference in activity is 
sufficiently great to offer hope that further chemical elaboration, in particular of the R2 
group, may allow distinguishing selectively between threonine-gatekeeper kinases of 
parasite and host. This extends the range of parasitic diseases potentially treatable with BKI 
drugs to include those caused by Plasmodium (Chapman, et al., 2013), Eimeria (Keyloun, et 
al., 2014), Theileria (Hines, et al., 2015), and Babesia (Pedroni, et al., 2016), all of which 
express threonine gatekeeper CDPKs. A validation of CDPK(s) as the sole molecular 
target(s) that cause inhibition of growth and proliferation of an apicomplexan parasite cells 
when exposed to BKIs will still need chemical genetic determination as demonstrated in T. 
gondii.
3. Inhibition of Apicomplexan parasite growth and replication by BKIs
3.1. Toxoplasma
Toxoplasma gondii is a protozoan parasite that is broadly distributed throughout the world 
infecting mammals and birds, providing a large reservoir for human infection (Tenter, et al., 
2000). Human toxoplasmosis is most often asymptomatic or causes mild, self-limited 
symptoms, which includes the formation of tissue cysts that persist in the host brain and 
other organs indefinitely. However, severe infections may cause blindness, disability or 
death. Persons previously infected with T. gondii (and hence are still carrying parasite cysts) 
who have AIDS or who have undergone allogeneic stem cell transplantation are at the 
greatest risk of developing toxoplasmosis (Martino, et al., 2005). The primary disease 
manifestation in immunocompromised patients is encephalitis, although ocular, pulmonary 
and disseminated toxoplasmosis also occur (Rabaud, et al., 1994) . Healthy persons may 
develop uveitis, and relapsing uveitis may lead to retinal scarring and loss of vision. The 
incidence of ocular disease varies geographically and is noted to be exceptionally high in 
areas of Brazil, possibly due to the prevalence of genetically distinct strains that circulate in 
South America (Dubey, et al., 2012, Khan, et al., 2006). Toxoplasma encephalitis and 
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relapsing ocular disease result from the reactivation of tissue cysts, which are not eliminated 
by currently used anti-Toxoplasma medicines. Congenital toxoplasmosis results when an 
initial primary infection of a pregnant woman spreads to the fetus, which may cause 
miscarriage or developmental defects in the brain and eyes. Other human to human 
transmission is restricted to transfusions or transplants, reducing the propensity for the 
spread of drug resistance.
First line therapy for toxoplasmosis, the combination of pyrimethamine and sulfadiazine, has 
a high rate of toxic side effects that can lead to discontinuation of treatment (Dannemann, et 
al., 1992, Katlama, et al., 1996, Porter and Sande, 1992). Therapy for Toxoplasma 
encephalitis begins with six weeks of treatment that is then continued until immune 
reconstitution. The duration of treatment for congenital infection is at least one year while 
ocular infection is four to six weeks and may be extended to prevent relapse (Harrell and 
Carvounis, 2014, McLeod, et al., 2006). Improved therapy for toxoplasmosis would be 
orally available for use in resource-poor settings, achieve high brain and eye concentrations 
to treat encephalitis and uveitis and would be active against both the acute replicating 
tachyzoite and latent bradyzoite stages within tissue cysts. Moreover, new drugs should also 
prioritize having fewer, milder side effects and being effective in pregnancy.
Inhibition of T. gondii calcium-dependent protein kinase 1 (TgCDPK1) has proven to be 
effective in models of experimental toxoplasmosis. TgCDPK1 regulates the calcium-
dependent pathway of T. gondii microneme secretion and is required for gliding motility, 
host cell invasion and host cell egress (Lourido, et al., 2010). BKIs have been shown to halt 
T. gondii proliferation by blocking host-cell invasion and egress (Lourido, et al., 2010, 
Murphy, et al., 2010, Ojo, et al., 2010). However, parasites overexpressing CDPK1 with its 
glycine gatekeeper replaced by methionine are resistant to multiple BKIs (Johnson, et al., 
2012, Ojo, et al., 2010, Vidadala, et al., 2016). Interestingly, T. gondii mitogen-activated 
protein kinase like 1 (TgMAPKL1, which has a serine gatekeeper) has been described as a 
secondary target for the BKI 1NM-PP1, based on the finding that a mutation in its 
gatekeeper residue was associated with decreased susceptibility to 1NM-PP1 and similar 
BKIs (Sugi, et al., 2015). Polypharmacology is common with kinase inhibitors, so it will be 
important to evaluate each BKI for its target specificity.
BKI synthesis based on the PP scaffold has resulted in potent TgCDPK1 inhibitors (Johnson, 
et al., 2012, Larson, et al., 2012, Murphy, et al., 2010, Vidadala, et al., 2016). Lourido et al. 
(2013) described a series of PP analogs. In this series, compounds 11 and 24 were 
metabolically stable and had in vitro EC50s of 250 nM and 610 nM. These compounds 
increased 30 day survival in mice infected with the type II Pru-LUC strain and decreased 
brain cysts when administered intraperitoneally prior to infection at 5 mg/kg for 10 days 
(Lourido, et al., 2013). Larson et al reported that development of the PP scaffold by adding a 
6-alkoxy-2-naphthyl group at the R1 position, and a 4-piperidinylmethylene group at the R2 
position further increased selectivity (Doggett, et al., 2014, Larson, et al., 2012). These BKIs 
were >15,000 fold more active against TgCDPK1 compared to the human kinases SRC and 
ABL (which are among the rare human kinases with threonine gatekeeper residues), with no 
inhibition of the human kinases at 20 μM. BKI-1294 (Fig. 3), which was synthesized with 
N-methylation of the 4- piperidinyl-methylene substituent to improve metabolic stability, 
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had an in vitro EC50 of 140 nM and reduced acute T. gondii infection in mice by 93% when 
given orally (or per os, P.O.) at 30 mg/kg (Doggett, et al., 2014). Upon further testing, 
BKI-1294 was found to inhibit the human Ether-à-go-go-Related Gene (hERG) ion channel, 
preventing further advancement for human toxoplasmosis due to the risk of cardiotoxicity. 
Vidadala et al., 2016 investigated modifications of the PP scaffold that maintained efficacy 
and selectivity for TgCDPK1 while eliminating hERG liability. Compound 32, also known 
as BKI-1553 (Fig. 3), in their series of BKIs had a > 10 μM IC50 against hERG, a 60 nM in 
vitro EC50 against T. gondii. BKI-1553 eliminated peritoneal T. gondii infection when 
administered P.O. to mice at 20 mg/kg for 5 days. In the latent T. gondii infection model 
using the ME49 strain, 30 mg/kg of BKI-1553 reduced the number of brain tissue cysts by 
89%. Pharmacokinetic studies in non-infected mice demonstrated a brain to plasma 
concentration ratio of 0.33 (Vidadala, et al., 2016), indicating good penetration for treatment 
of brain cysts.
Development of the 5-aminopyrazole-4-carboxamide (AC) scaffold identified BKIs 1586 
and 1643 as lead compounds (Fig. 3). BKI-1643 had an in vitro EC50 of 45 nM against T. 
gondii, and in an acute in vivo model using the RH strain, BKI-1643 reduced infection in the 
peritoneum below the limits of detection when given P.O. at 20 mg/kg for 5 days (Huang, et 
al., 2015). BKIs 1586 and 1643 had a brain to plasma concentration ratio of 0.16 and 0.43, 
respectively.
In addition to the PP and AC scaffolds, an in vitro screen of a library of compounds against 
T. gondii identified biphenylimidazoazines as inhibitors of T. gondii growth (Moine, et al., 
2015). Subsequently, a series of 14 imidazo[1,2-b]pyridazines based on the 
biphenylimidazoazines were found to inhibit TgCDPK1 in enzymatic studies at IC50s < 1μM 
and 7 compounds were found to inhibit T. gondii at EC50s < 1 μM. Several compounds in 
this series were found to have EC50s at or below 100 nM against T. gondii with minimal host 
cell toxicity, but they could not be further advanced due to pharmacokinetic issues (Moine, 
et al., 2015). At this point in preclinical development, BKIs possess the desirable 
characteristics of a new drug for toxoplasmosis: oral bioavailability, brain tissue penetration, 
pharmacokinetics that allow for once daily dosing, efficacy against acute and latent stages of 
T. gondii and no evidence of host toxicity. Although studies to identify the best BKI are 
ongoing, several suitable candidates for advanced drug development have emerged. The 
spread of drug resistance resulting from drug exposure is very unlikely given the rarity of 
human-to-human transmission of T. gondii, however, the development of resistance in 
individuals during treatment should be investigated. Given the promising results that have 
come from the extensive preclinical evaluation of the BKI class of compounds, BKIs 
demonstrate great potential for expanding and improving therapy for toxoplasmosis.
3.2. Neospora
Neospora caninum is phylogenetically closely related to Toxoplasma gondii, but several 
biological features distinguish these two species, including elements of their life cycle, host 
range, pathogenicity and ultrastructure (Hemphill, et al., 2016). Canids, namely dogs, 
wolves, dingoes and coyotes, represent definitive hosts, and N. caninum is capable of 
infecting and proliferating within a wide range of intermediates hosts, including cattle, 
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sheep, goats, and many more (Dubey and Dubey, 2003). Extensive proliferation can lead to 
cellular destruction, tissue damage and immunopathology, and thus disease within these 
hosts. Neospora infections in humans have never been demonstrated. The parasite owes its 
economic importance primarily to the fact that it causes abortion in cattle, and stillbirth 
and/or birth of weak calves, with estimated annual losses of around 1.3 billion US dollars in 
the 10 countries where data is available (Reichel, et al., 2013). Natural N. caninum infection 
in sheep and concomitant Neospora-induced abortion problems have also been reported 
(Gonzalez-Warleta, et al., 2014, Moreno, et al., 2012). In addition, N. caninum infection can 
result in birth of clinically healthy, but persistently infected calves, which in turn then 
vertically transmit the parasite to the next generation. A number of proposed control options 
have been modeled, such as testing and culling of seropositive animals, discontinued 
breeding with offspring from seropositive cows, and vaccination of susceptible and infected 
animals. However, despite enormous efforts, vaccination against neosporosis has proven to 
be difficult, thus more recently chemotherapeutical treatment options are being considered 
as a potential alternative to limit the economic impact of neosporosis (Monney and 
Hemphill, 2014).
In general, chemotherapeutic treatment of Neospora-seropositive animals has not been 
regarded as an economically viable option, especially since depending on the compounds 
used, milk or meat from drug-treated animals would remain unacceptable for consumption 
for some time (Dubey, et al., 2007). Nevertheless, experimental studies have revealed 
potentially interesting effects of several compounds in vitro and in laboratory animal models 
in vivo (reviewed in Hemphill et al., 2016). Many of these compounds or compound classes 
were shown previously to be active against other intracellular protozoan parasites, including 
Trypanosoma cruzi, the causative agent of Chagas Disease, and Leishmania species 
responsible for cutaneous and visceral leishmaniasis, and some exhibited broad-spectrum 
anti-parasitic activity against various protozoans and helminths. However, other approaches 
identified compounds that inhibited targets that were conserved almost exclusively within 
the group of apicomplexan parasites. BKIs that target CDPK1 represent a classical example 
of such a targeted cross-species approach.
Molecular, structural and phenotypic evidence demonstrated that NcCDPK1 is a promising 
molecular target for neosporosis drug development. Recombinant NcCDPK1 was expressed, 
purified and screened against a select group of bumped kinase inhibitors (BKIs) previously 
shown to have low IC50s against T. gondii CDPK1 and T. gondii tachyzoites. NcCDPK1 was 
inhibited by low concentrations of BKIs, and BKI-1294 was chosen as a lead compound 
(Ojo, et al., 2014). The three-dimensional structure of NcCDPK1 in complex with BKI-1294 
was studied crystallographically, demonstrating the structural basis for binding and 
selectivity. Calcium-dependent conformational changes in solution as characterized by 
small-angle X-ray scattering are consistent with previous structures in low calcium-state but 
different in the calcium-bound active state than predicted by X-ray crystallography (Ojo, et 
al., 2014). This implies that additional structural states of CDPK1 exists beyond the X-ray 
crystallographic structures with and without bound calcium.
The compound interferes in Neospora host cell invasion and egress, and prolonged exposure 
results in the formation of multinucleated parasites, trapped within host cells (Ojo, et al., 
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2014). BKI-1294 exposure in vitro is not directly parasitocidal: only upon long-term in vitro 
treatment of infected host cells (>20 days), was a complete clearance of viable tachyzoites 
observed. For different Neospora isolates such Nc-1, Nc-Liv, and Nc-Spain7, but also for T. 
gondii strains RH and ME49, clearance of intracellular parasites is also always preceded by 
the formation of multinucleated parasites with a deregulated gene expression pattern as 
evidenced by the simultaneous expression of bradyzoite and tachyzoite antigens (Fig. 4) 
(Winzer, et al., 2015).
In vivo treatment with BKI-1294 in a standardized neosporosis mouse model (Arranz-Solís, 
et al., 2015) is highly efficacious in non-pregnant mice: Oral dosing of BKI-1294 at 50 
mg/kg for 5 days in established murine neosporosis resulted in a 10-fold reduced cerebral 
parasite burden compared to untreated controls. In addition, BKI-1294 used at the same 
dosage did not show any adverse effects in pregnant mice nor in their offspring. BKI-1294 is 
the first compound tested so far that achieved excellent protection against vertical 
transmission of N. caninum, with only 5% offspring mortality compared to 100% in the 
placebo group, and less than 10% of offspring PCR positive in the CNS, compared to 100% 
positive in the placebo group (Winzer, et al., 2015). Thus, these data demonstrate proof-of-
concept for BKIs, and 1294 specifically, for therapy of bovine and canine neosporosis, and 
BKI-1294 is a prime candidate for further follow-up studies in larger animals. In addition, 
other BKIs are currently evaluated in vitro and in vivo.
3.3. Sarcocystis
Sarcocystis neurona is the primary causative agent of equine protozoal myeloencephalitis 
(EPM), which is a serious neurologic disease that impacts horses in North and South 
America (Dubey, et al., 2015, Howe, et al., 2014). The clinical signs of EPM are variable 
and can range from acute to chronic, with the potential for neuropathology in all areas of the 
central nervous system (CNS) although the spinal cord is most commonly affected. EPM 
horses may exhibit a gradual progression of clinical signs such as mild lameness and 
asymmetric muscle atrophy, while acutely-affected horses can progress quickly to severe 
ataxia or recumbency. Without adequate treatment, the disease is typically fatal. Notably, S. 
neurona has also been found to be a significant cause of morbidity and mortality in assorted 
marine mammals, including sea otters, seals, and sea lions (Carlson-Bremer, et al., 2012, 
Dubey, et al., 2001, Lapointe, et al., 1998, Lindsay, et al., 2001, Miller, et al., 2010, 
Rosonke, et al., 1999).
Like its close relatives T. gondii and N. caninum, S. neurona has an obligatory two-host life 
cycle that includes the opossums Didelphis virginiana in North America (Fenger, et al., 
1995) and Didelphis albiventris in South American (Dubey, et al., 2001) as the definitive 
host. The natural intermediate hosts are various small mammals such as skunks (Cheadle, et 
al., 2001), raccoons (Dubey, et al., 2001), and armadillos (Cheadle, et al., 2001). Horses and 
marine mammals become infected when they ingest S. neurona sporocysts/oocysts that have 
been passed in the feces of infected opossums.
The traditional anti-folate drug combination of pyrimethamine and a sulfonamide has been 
used for decades to treat EPM, with daily administration for at least six months considered 
the standard therapy. While rarely serious, the anti-folate drugs can have side effects such as 
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bone marrow suppression, anorexia, diarrhea, mild anemia, and neutropenia, and 
pyrimethamine is a teratogen that should not be given to pregnant mares (Reed, et al., 2016). 
More recently, diclazuril and ponazuril have been developed and approved for use as a 
treatment for EPM (Dirikolu, et al., 2006, Furr, et al., 2001, Mackay, et al., 2008). These two 
drugs have broad anticoccidial activity in a variety of animal species and are 
benzeneacetonitrile compounds related to the herbicide atrazine (Hackstein, et al., 1995). 
Nitazoxanide (NTZ) is a broad-spectrum antimicrobial drug that was approved and marketed 
for treatment of EPM. Although an effective therapy for treatment of S. neurona infection, 
the broad-spectrum activity of NTZ was associated with adverse side-effects in horses (e.g., 
colic), so this drug is no longer available for treatment of EPM.
Interrogation of S. neurona genome and transcriptome information revealed a CDPK1 
homologue with the glycine “gatekeeper” residue found in other apicomplexans, thus 
implying that BKIs might be effective against S. neurona infection and EPM. Detailed 
examination showed that BKIs bind and inhibit recombinant SnCDPK1 in vitro, and S. 
neurona in cell culture was inhibited by four different BKIs at EC50 values of 40–120 nM 
(Ojo, et al., 2016). Based on the timing of treatment, it appeared that host cell invasion by 
the parasite was blocked by the BKIs, consistent with the role of CDPK1 for regulating 
parasite motility and host cell entry (Lourido, et al., 2010, Lourido, et al., 2012, Ojo, et al., 
2010). However, higher BKI concentrations resulted in delayed S. neurona endopolygeny 
and apparent arrest just prior to formation of daughter merozoites. These results suggested 
that BKI treatment at elevated concentrations might inhibit a second target related to S. 
neurona development and cytokinesis, similar to what was observed for N. caninum and T. 
gondii (Ojo, et al., 2014, Winzer, et al., 2015). In vivo experiments in a murine model of 
sarcocystosis showed that treatment for 30 days with BKI-1553 protected S. neurona-
challenged mice. In contrast, challenged and non-treated control mice had severe signs of 
neurologic disease resulting in death or the need for euthanasia between 39 and 70 days 
post-inoculation. Histologic analysis and bioassay of brain tissues demonstrated parasites in 
all 10 non-treated control mice but in only 1 of the BKI-1553-treated mice, indicating that 
BKI treatment cleared infection in 90% of mice challenged with S. neurona. Importantly, 
BKI-1553 is one of several optimized BKIs lacking the potent hERG inhibitory activity that 
precluded the use of the initially-developed related BKI-1294 in humans-(Vidadala, et al., 
2016). Along with these improvements to reduce host toxicity, the experimental results 
examining BKI activity against S. neurona infection indicate that these compounds are 
promising candidates for developing a new therapy for horses afflicted with EPM.
3.4. Cryptosporidium
Cryptosporidiosis, a zoonotic or anthroponotic disease caused by the apicomplexan parasites 
of the genus Cryptosporidium, is a significant contributor to global diarrheal morbidity and 
mortality. Cryptosporidiosis is transmitted in the form of highly resistant, sporulated oocysts 
that are infectious at the time of passage and spread by the fecal-oral route. Presumptive 
diagnoses of Cryptosporidiosis in calves, for instance, could be made based on age, clinical 
signs and symptoms. Laboratory diagnosis is mostly based on identifying oocysts in feces. 
Infection takes root in the host’s intestinal epithelial cells and causes watery diarrhea that is 
typically self-limiting. However, there is a risk for severe disease in immunocompromised 
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persons, such as those suffering from AIDS and malnourished children in developing 
countries, with infection becoming persistent, recurring, and life-threatening (Fayer, 1997). 
Cryptosporidium has recently been identified as the second and third leading cause of 
moderate to severe diarrhea in infants aged 0 to 11 months and 12 to 23 months, 
respectively, in various regions of Africa and South Asia (Kotloff, et al., 2013). Current 
treatments for cryptosporidiosis, including nitazoxanide and paromomycin, have marginal 
efficacy of 1.7 days less diarrhea in normal hosts. These drugs are largely ineffective in 
immunocompromised patients and are not approved for use in children under 12 months old 
(Pantenburg, et al., 2009), the two groups most at risk from this disease, underscoring the 
urgent need for novel therapeutics.
Like TgCDPK1, C. parvum CDPK1 (CpCDPK1) contains a glycine residue at the 
gatekeeper position (Murphy, et al., 2010). For this reason and because of the homology of 
the solved crystal structures of the ATP binding sites of Tg and CpCDPK1, BKIs 
synthesized to target TgCDPK1 have been analyzed for activity against CpCDPK1. BKIs 
were evaluated in vitro to determine enzymatic IC50s against CpCDPK1 and cellular EC50s 
against C. parvum cultured in HCT-8 cells. Three of the most potent compounds were the PP 
compounds BKI-1294 and BKI-1553, and the AC compound BKI-1517 (Fig. 3) 
(Castellanos-Gonzalez, et al., 2016, Castellanos-Gonzalez, et al., 2013, Schaefer, et al., 
2016). These compounds were subsequently assessed in vivo for efficacy in various mouse 
and calf models.
SCID-beige mice infected by oral gavage with C. parvum were dosed P.O. with BKI-1294 at 
100 mg/kg or vehicle alone for 10 days (4–14 days post-infection). Those treated with 
BKI-1294 showed significant reduction in oocyst shedding and eventual clearance, with only 
1 of 7 mice shedding oocysts by 33 days post-infection compared to 6 of 7 control mice 
shedding at 33 days post infection (Castellanos-Gonzalez, et al., 2013). Hematoxylin-eosin 
stained sections of intestine from mice treated with 1294 displayed a lack of damage to the 
intestinal epithelium and a lack of excess apoptotic cells, both of which were observed in the 
C. parvum infected control mice but absent in uninfected controls (Castellanos-Gonzalez, et 
al., 2013). Similarly, mice treated with BKI-1517 at 60 mg/kg and 120 mg/kg P.O. for 5 days 
also showed significant reduction in oocyst shedding (Castellanos-Gonzalez, et al., 2016). At 
the higher dose, infection was completely cleared out to 28 days post-infection in 5 of 6 
mice; at the lower dose infection was reduced, with only 3 of 6 mice shedding oocysts at 28 
days (Castellanos-Gonzalez, et al., 2016).
Lead BKIs were also screened in vivo against C. parvum infection in neonatal ICR mice 
(Schaefer, et al., 2000, Schaefer, et al., 2016). Eight day old mice received a dose of 25 
mg/kg of BKI concurrently with infection, then dosed again at 3 hours post-infection (HPI) 
and every 12 hours thereafter for nine total doses. Histological examination of the jejunum, 
ileum, cecum, and colon showed a 56%, 38%, and 36% reduction of infection in mice 
treated with BKI-1294, BKI-1517, BKI-1553 respectively, or (Schaefer, et al., 2016). 
Paramomycin treatment of neonates showed significantly lower efficacy, with a reduction of 
15% (Schaefer, et al., 2016).
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The same three BKIs were next evaluated in a clinical disease model, treating neonatal 
calves infected with C. parvum at 36 to 48 hours old (Imboden, et al., 2012, Schaefer, et al., 
2016). BKI-1294 was dosed in two different groups: group A was given 4 doses total at 10 
mg/kg, once daily at 48, 96, 144, and 192 hours-post-infection (HPI); and group B was given 
10 doses total at 5 mg/kg every 12 hours 48 - 156 HPI. Treatment group A showed 
improvement in daily clinical health scores, increased total urine output, and firmer fecal 
consistency, in addition to reduced weight loss and fewer oocysts shed daily when compared 
to controls (Schaefer, et al., 2016). However, while this treatment did not reduce total fecal 
output when compared to controls, drug concentrations in plasma and stool were 
subsequently determined by LC-MS analysis to be below therapeutic levels (essentially 
zero) by 48 hours after each dose (Schaefer, et al., 2016). This partial success inspired the 
repeat trial, dosing BKI-1294 at 12 hour intervals (group B), which showed significant 
improvements over control calves in daily clinical health scores, decreased duration of 
diarrhea, decreased total fecal output and firmer fecal consistency, decreased weight loss, 
and decreased number of oocysts shed (Schaefer, et al., 2016). BKIs 1517 and 1553 were 
also dosed a total of 10 times at 12 hour intervals starting at 48 HPI at 10 mg/kg and 5 
mg/kg, respectively. Both also showed significant improvements over control calves in all 
parameters when dosed every 12 hours, with the single exception that BKI-1553 failed to 
reduce total fecal volume (Schaefer, et al., 2016). Neonatal calf studies showed that, overall, 
all three BKIs reduced cryptosporidiosis symptoms and infection levels, with BKIs 1294 and 
1517 showing slightly better outcomes compared to BKI-1553 (Schaefer, et al., 2016).
3.5. Plasmodium
Malaria remains a major cause of morbidity, afflicting over two hundred million people 
annually (World Health Organization., 2014). Despite years of exposure to intense malaria 
transmission; individuals living in endemic areas have no evidence of sterile immunity to P. 
falciparum infection (Tran, et al., 2013). Infections are transmitted through bites of infected 
female Anopheles mosquitoes. Infection of humans is primarily due to four Plasmodium 
species, namely P. falciparum, P. vivax. P. malariae, and P. ovale. A fifth species, P. 
knowlesi, emerging in Malaysia, is reported to cause a zoonotic malaria in humans 
(Jongwutiwes, et al., 2004). Malaria parasites alternate between different stages in both 
mammalian (asexual) and mosquito (sexual) hosts. Currently used drugs for treatment of 
clinical symptoms of malaria erythrocytic (asexual) stage do not prevent the sexual forms 
(gametocytes) from infecting mosquitoes, even when prevalence and density of gametocytes 
appear low (Schneider, et al., 2006). Even treatment with the two drugs with anti-gametocyte 
activity, primaquine and artemisinin combination therapy, are imperfect in stopping 
Plasmodium transmission to mosquitoes. Primaquine kills mature but not immature 
gametocytes, while artemisinin combination therapy kills immature but not mature 
gametocytes (Bousema and Drakeley, 2011, Wilairatana, et al., 2010). Atovaquone was 
recently shown to as a strong inhibitor of P. berghei ookinete formation (Delves, et al., 2012) 
which makes it a good candidate for malaria transmission blocking indication.
The lack of effective transmission-blocking gametocides is a problem for malaria control 
because circulating gametocytes that are infectious to mosquitoes persist for weeks after 
anti-malarial therapy (Bousema and Drakeley, 2011, Bousema, et al., 2010). Treated 
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individuals, often without symptoms, continue to transmit malaria to abundant mosquitos, 
since effective control of Anopheles mosquitoes also remains a formidable challenge 
(Wellems, et al., 2009). This emphasizes the need for interventions that prevent parasite 
transmission.
Transmission of malaria parasites and effective transition between these different stages of 
life in mammalian and mosquito hosts require elaborately coordinated signal transduction 
(Ojo, et al., 2012, Vidadala, et al., 2014). Controlled shifts between high and low levels in 
intracellular calcium concentrations have been speculated to influence many of these 
processes. Intracellular calcium levels in infectious apicomplexan parasites have long been 
associated with invasion, gliding motility, and the secretory pathway; elements that are likely 
interrelated (Nagamune and Sibley, 2006). We have recently developed an extended 
spectrum class of BKIs to disrupt the transmission of malaria parasites from humans to 
mosquitos. It has been demonstrated using chemical genetics that the mechanism of action 
of these BKIs is through inhibition of Plasmodium calcium dependent protein kinase 4 
(CDPK4) (Ojo, et al., 2014, Ojo, et al., 2012). Previous studies have shown that BKIs, when 
ingested by mosquitoes during a blood meal containing malaria gametocytes, inhibit CDPK4 
activity and this prevents exflagellation of the male gametocytes (Ojo, et al., 2014, Ojo, et 
al., 2012). Exflagellation is the visible outcome of the maturation and activation of male 
gametocytes into sperm-like, male gamete cells needed for fertilization of the female 
gametes. In simple terms, BKIs act as malaria birth control pills that stop the transmission of 
malaria by blocking the mating and further parasite development to infectious stages in the 
mosquito. Thus, BKIs could fill an important but often overlooked gap in malaria control. To 
block transmission, BKIs must be present in the blood constantly while gametocytes are 
present and when a mosquito bites. These parameters therefore require that the inhibitor 
needs to be non-toxic, long lasting, and effective at doses that permit long-term treatment 
exposure in humans. Highly selective transmission blocking BKIs (Ojo, et al., 2014, Ojo, et 
al., 2012, Vidadala, et al., 2014) were successfully designed because the serine gatekeeper 
residue in Plasmodium CDPK4 is smaller than that of almost all human kinases. Additional 
specificity and potency was provided by the unique conformation of the active site and 
hydrogen-bonding sites available to small molecule inhibitors, as well as structural features 
that can be exploited to gain further selectivity, as discussed in detail above (Ojo, et al., 
2014, Ojo, et al., 2012, Vidadala, et al., 2014). Specific inhibition of CDPK4 does not appear 
to inhibit the asexual blood stages of malaria since most of the asexual stage activity was 
lost from our BKI series during optimization for CDPK4 kinase activity and specificity (Ojo, 
et al., 2014, Ojo, et al., 2012, Vidadala, et al., 2014). This is important in preventing the 
evolution of resistance to BKI drugs. Drugs with activity against asexual parasites regularly 
contact their targets in the 1011 to 1012 asexual stage parasites in each person, increasing the 
chance of encountering (and selecting) a resistant parasite. Because only about 10 
gametocytes are taken up by each mosquito, and BKIs only act against gametocytes in the 
mosquito, the likelihood of BKIs encountering a resistant parasite is extremely low. Thus 
BKIs could be part of a malaria combination therapy that could stop transmission of 
parasites that become resistant to the other components that alleviate the malaria illness.
The active sites of Plasmodium spp. CDPK4 enzymes are highly homologous. We have 
demonstrated that BKIs block both rodent and human malaria transmission to mosquitoes 
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(Ojo, et al., 2012). This data suggests that BKIs and related compounds are likely to be 
useful in blocking the transmission of all five species known to cause human malaria; a 
significant public health benefit.
3.6. Babesia
Babesiosis is a zoonotic disease caused by the apicomplexan genus, Babesia. With more 
than 100 species currently recognized, these hemoparasitic protozoans inflict asymptomatic, 
mild to fatal diseases to a large diversity of animals including humans. The most 
economically devastating disease is bovine babesiosis. Two major Babesia species, B. bovis 
and B. bigemina, are responsible for this significant agricultural problem with the latter 
species causing a milder illness to livestock. Most often exhibited symptoms are the 
characteristic high fever, anemia, anorexia, hemoglobinuria with periodic neurological 
sequelae such as incoordination, tilting of the head, teeth grinding, involuntary movements 
of the legs and excess salivation caused by B. bovis. In severe and often fatal cases, B. bovis-
infected animals eventually suffer from cerebral babesiosis. Bovine babesiosis is a disease of 
the adult animals as juveniles are immune until they are at least 6-8 months old (Brown, et 
al., 2006, Taylor, et al., 1983). It is endemic to most of the world, and the distribution of the 
disease is entirely dependent upon the geographical localization of the tick vector, 
Rhipicephalus sp. Countries in Asia, South America, Australia, Europe and Africa are all 
affected. North America such as the US is almost devoid of bovine babesiosis due to an 
effective, well-coordinated tick eradication program that started in the 1940s. However, an 
increase in acaricide resistance of the tick vector and global animal movement are 
contributing to the re-emergence of bovine babesiosis in the US. In contrast to animal 
babesiosis, human babesiosis, caused by B. microti, has not always been on the radar of 
disease surveillance in the US. This tick-borne disease is currently a public health issue, 
especially in the Northeast corridor of the US. There, B. microti shares its vector host with 
Borrelia sp., the causative agent of Lyme disease. Thus, it has been reported that some Lyme 
disease patients also suffer from human babesisosis (Diuk-Wasser, et al., 2016, Knapp and 
Rice, 2015).
There has been substantial research effort and financial funding over the years to develop 
preventive and chemotherapeutic remedies against babesiosis for the veterinary and medical 
world. Currently, live attenuated vaccines are available for combating veterinary babesiosis 
and are widely used in endemic countries such as Australia and Argentina (Gohil, et al., 
2013). For non-endemic countries such as the United States where treatment is the preferred 
option, imidocarb dipropionate (3.5 mg/kg) intramuscularly administered is effective 
although residual drug metabolite renders the treated animal unmarketable (Coldham, et al., 
1995). For human babesiosis, antibiotic combination therapy is available (Homer, et al., 
2000). However, due to side effects and long treatment regimen, improved treatment 
therapies are desired (Vannier, et al., 2015).
BKIs have been established to be specifically inhibitory against apicomplexans such as 
Plasmodium, Toxoplasma and Cryptosporidium (see above). Out of >600 of these BKIs 
available for testing, a subset was chosen to evaluate if they would inhibit Babesia growth 
within the mammalian host (Keyloun, et al., 2014). Using the B. bovis model system to 
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evaluate the drug effect, 12 BKIs were selected and added to the growth media of the 
parasite culture (Pedroni, et al., 2016). As expected, inhibition ranged from non-responsive 
to lethal as compared to the control group. Of the BKIs that were inhibitory, their anti-
proliferative action was observed as early as 24 hours post-treatment. No specific cellular 
phenotypic effect was observed, except for BKI-RM-1-152, which 30 μM constant exposure 
blocked egress from the infected erythrocytes, as parasites continued to replicate and 
accumulate, an observation shared with the Neospora parasites that are exposed to BKI-1294 
in vitro. This resulted in the accumulation of merozoite-like parasites crowding within the 
host erythrocyte although the overall erythrocyte size remained unchanged (Pedroni, et al., 
2016). BKI-RM-1-152’s effect was specific to the egression process as the removal of the 
drug led to successful egress of these merozoite-like parasites and the freed merozoites 
invaded more host cells. This result illustrated the static nature of this particular BKI.
BKIs clearly have a negative effect on Babesia and can be further exploited for the 
development of an effective, specific treatment option against babesiosis. Identification of 
the specific BKI target(s) in Babesia and subsequent optimization of the binding affinity of 
the BKIs to these targets are logical next steps. These small compounds may also assist in 
deciphering cellular pathways of Babesia such as egress, invasion and replication, where 
these and many other metabolic pathways remain a significant knowledge gap in this 
parasite field.
3.7. Theileria
Theileria equi is a tick-transmitted apicomplexan hemoprotozoan parasite of equids and an 
etiologic agent of equine piroplasmosis (EP), a World Organization for Animal Health (OIE) 
reportable disease. T. equi occurs worldwide where tick vectors are present, and it is 
estimated that only 10% of the world's equids reside in regions free of EP (de Waal, 1992). 
Although the continental USA was declared free of EP in 1988 (United States. Animal and 
Plant Health Inspection Service., 2008), several well-described outbreaks of T. equi have 
occurred recently in U.S. horses (Scoles, et al., 2011, Short, et al., 2012, Ueti, et al., 2012, 
United States. Animal and Plant Health Inspection Service., 2008).
Although prevention of infection and disease would be ideal, complete control of tick 
vectors is extremely difficult, and vaccines against T. equi do not exist. Treatment of infected 
animals with the goal to clear infection and eliminate the risk of transmission represents a 
feasible strategy for disease control in some regions. Imidocarb dipropionate, a dicationic 
diamidine of the carbanilide series of antiprotozoal compounds, has been effective against 
some of the T. equi strains causing infections in U.S. horses (Ueti, et al., 2012), making it 
the current drug of choice. However, variable responses to imidocarb treatment occur in both 
natural and experimental T. equi infection (Butler, et al., 2008, Frerichs, et al., 1973, Grause, 
et al., 2013, Knowles, 1996, Kumar, et al., 2003, Kumar, et al., 2009, Kuttler, et al., 1987, 
Ueti, et al., 2012), and we have recently documented treatment failure associated with in 
vitro imidocarb resistance (Hines, et al., 2015). Moreover, acute adverse effects are common 
due to the anticholinesterase activity of the drug (Tecles and Cerón, 2001). These include 
spasmodic colic and diarrhea (Meyer, et al., 2005). Therefore, pretreatment with 
anticholinergic drugs such as atropine sulfate (Meyer, et al., 2005), glycopyrrolate 
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(Donnellan, et al., 2013), or N-butylscopolammonium bromide (Ueti, et al., 2012) is 
required. Imidocarb injections are painful and local injection site reactions are common 
(Meyer, et al., 2005). The LD50 is 16 mg/kg (only four times the therapeutic dose), and 
death is associated with dose-dependent nephrotoxicity and hepatotoxicity (Adams, 1981).
Because of the documented effectiveness of BKIs against other apicomplexans (reviewed 
herein), we recently evaluated the in vitro susceptibility of several T. equi isolates to both 
imidocarb dipropionate and to BKI-1294 (Hines, et al., 2015). Similar to other 
apicomplexans, T. equi CDPK1 has a small glycine gatekeeper residue within the ATP-
binding region (Hines, et al., 2015). Despite a difference in imidocarb susceptibility amongst 
isolates (EC50: 6.4 - 414 nM), we observed uniform susceptibility to BKI-1294, albeit at a 
considerably higher IC50 of approximately 4.0 μM. The relatively high hERG activity of 
BKI-1294 (IC50: 0.767 μM) (Ojo, et al., 2014) likely precludes its use in the horse for 
treating T. equi, especially given recent work documenting the sequence and functional 
homology of the equine hERG ortholog (Pedersen, et al., 2015). Ongoing work includes 
screening additional BKI compounds for those with higher activity against T. equi coupled 
with lower to absent hERG activity. Given the large number of recently developed BKI 
compounds, it is possible that a promising nontoxic alternative to imidocarb dipropionate 
will be identified for the treatment of horses infected with T. equi.
3.8. PK and Safety of Lead BKIs
Single Dose—While the efficacy of our BKIs against CDPK1 and apicomplexan parasites 
are similar for the lead drug candidates, these compounds display diverse in vivo efficacy in 
each of the animal models. It is possible that the in vivo variability in BKI efficacy may be 
related to their absorption, distribution, metabolism, and elimination (ADME) properties. 
Indeed the pharmacodynamics for BKIs against T. gondii and C. parvum might be expected 
to be completely different, as T. gondii need to be treated by a systemically-distributed 
compound with blood-brain-barrier permeability, whereas C. parvum therapy would need to 
reach the large bowel, where C. parvum resides on the apical side of intestinal epithelial 
cells. In our evaluation pipeline, we initially characterized the pharmacokinetics of BKIs by 
administering a 10 mg/kg P.O. dose to BALB/c mice. In addition, a single 25 mg/kg P.O. 
dose of BKI was administered to characterize the fecal levels of the compounds.
The pharmacokinetic data for our three lead BKIs in adult BALB/c mice indicate that BKIs 
1517 and 1553 have higher systemic peak plasma concentrations (Cmax) and plasma 
exposures (AUC) compared to BKI-1294 (Table 1) (Huang, et al., 2015, Vidadala, et al., 
2016). BKI-1553 is more tightly bound to plasma proteins than the other two BKIs in mouse 
plasma. In addition, BKI-1553 has the largest systemic exposure; over four-fold greater than 
BKI-1517, largely because BKI-1517 is cleared more rapidly than BKI-1553.At this time it 
is unclear whether systemic concentrations drive the in vivo efficacy of BKIs for 
cryptosporidiosis (which is restricted to the gut), though the correlation is quite tight for 
toxoplasmosis. Therefore, it is important to note that in a mouse single dose model (25 
mg/kg P.O.), the fecal concentrations of BKI-1294 are greater than BKIs 1553 and 1517 
(Schaefer, et al., 2016).
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The bioavailability of BKIs 1294 and 1553 was evaluated by characterizing the 
pharmacokinetics of each BKI after intravenous (I.V.) and P.O. dosing in rats. Following I.V. 
administration to rats, BKI-1553 displayed biphasic kinetics and distributed approximately 
to total body water with a volume of distribution at steady state (Vss) of 0.9 L/kg. Following 
P.O. administration to rats, BKI-1553 showed slow absorption, with the absorption phase 
continuing for 12 hours. The plasma concentrations over the 24 hour period after P.O. dosing 
exceeded those observed after I.V. dosing suggesting that BKI-1553 had essentially 
complete bioavailability in rats and was greatly improved compared to that of BKI-1294 
(46%). Additional studies with BKI-1553 demonstrate that BKI-1553 has a bioavailability of 
86% in dogs and 65% in monkeys. Why the bioavailability of BKI-1553 is higher in mice 
compared to dogs and monkeys is not clear at this time.
In addition to mice, we have used calves as a pharmacokinetic and efficacy model for BKIs. 
The pharmacokinetics of BKIs 1294, 1517, and 1553 were determined after a single P.O. 
dose (10 mg/kg) (Schaefer, et al., 2016, Vidadala, et al., 2016). Similar to the results 
observed in the mouse model, BKI-1553 had the highest Cmax value and largest AUC (Table 
2) (Vidadala, et al., 2016). In addition, the rank order of t1/2 was the same in mice and 
calves. However, unlike the mouse model, BKI-1294 has a smaller oral clearance than 
BKI-1517 in the calf model, which results in an increased systemic exposure of BKI-1294 
compared to BKI-1517 (Schaefer, et al., 2016, Vidadala, et al., 2016). Differences in 
bioavailability between the animal models are possible explanation for this disparity.
Multiple Dosing—Tolerability and linear pharmacokinetics for BKI-1553 were evaluated 
after multiple doses in a mouse model. BKI-1553 was administered at 50 mg/kg every other 
day for 5 doses to mice, and plasma concentrations remained >10 μM for the entire duration 
of the study with maximum concentrations reaching 43 μM (Vidadala, et al., 2016). The 
exposure to BKI-1553 following the last 50 mg/kg dose was higher than what would be 
predicted from the single dose studies. The longer t1/2 suggests possible saturation of 
metabolism at this dose. A final blood collection was performed at the end of the study and 
all blood chemistry results were reported by Phoenix Central Laboratory to be within a 
normal range for species and age.
In addition to mice, the pharmacokinetics of BKIs 1294, 1553, and 1517 were characterized 
after multiple doses of BKI to calves. Calves were dosed separately P.O. with either 5 mg/kg 
(BKIs 1294 or 1553) or 10 mg/kg (BKI-1517) twice a day for five days (Schaefer, et al., 
2016). Overall, the steady state concentrations observed in the calves were within twofold of 
those predicted from the single dose data. As expected, steady state plasma concentrations 
for BKI-1553 were approximately 25-fold higher than BKIs 1294 and 1517(Schaefer, et al., 
2016). The ability to accurately predict the steady state concentrations of each BKI indicates 
that there is no saturation of metabolism with these dosing conditions. Furthermore, even 
during infection steady state concentrations for BKIs 1517 and 1553 could be accurately 
predicted using the single dose data from healthy calves. This suggests that the disease 
pathology does not have a significant impact on systemic concentrations of BKI, although 
further studies are warranted.
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Toxicity—BKIs 1294, 1553, and 1517 were initially screened for cytotoxicity against two 
mammalian cell lines HepG2 (liver) and CRL-8155 (lymphoblast). None of these three BKIs 
display any signs of toxicity at concentrations of up to 30 μM. In vivo toxicity for BKI-1294 
was initially screened by dosing at 40 mg/kg three times a day, and the mice appeared 
healthy. In addition, BKI-1294 was not toxic when dosed P.O. at 100 mg/kg daily for 5 days. 
Potential toxicity of BKI-1553 was examined in mice by testing two doses (30 mg/kg and 
100 mg/kg P.O.) daily for 5 days while observing mice for signs of toxicity and collecting 
blood samples. Both groups of mice remained active, well-groomed and appeared healthy 
throughout the study. Upon necropsy, there were no gross abnormalities, but histology 
revealed mild focal inflammation in the spleen in two of three mice in the 30 mg/kg group. 
The only abnormality observed in the 100 mg/kg group was inflammatory infiltrate in the 
hepatic lobules in one of three mice. BKI-1517 was dosed at 100 mg/kg once a day for 5 
days. Over days 2–5 the mice became less groomed and demonstrated less activity. When 
the dose was reduced to 53 mg/kg on day 1 and then 26.5 mg/kg once a day for four days, 
the mice remained well-groomed and healthy on each day.
We completed a maximally tolerated dose study to determine the lowest observable adverse 
effect level (LOAEL) and the no observable adverse effect level (NOAEL) of BKI-1553. 
Mice were dosed with single P.O. doses ranging from 200 mg/kg to 1000 mg/kg. The 
LOAEL was observed at 500 mg/kg, and the NOAEL was observed at 400 mg/kg. Mice had 
slightly ruffled fur and were less active than the control mice at 3 h following the 500 mg/kg 
dose. The lowered activity persisted at 24 hours, but was resolved by 30 hours. In addition, 
toxicity in calves was not observed for BKIs 1294 1517, or 1553, but the doses used were 
much lower (Schaefer, et al., 2016).
4. Conclusion
This review has focused on the utility of BKIs for therapy and prevention of apicomplexan 
infections. It is clear that the BKIs will have great utility against those organisms with the 
smallest gatekeepers in their CDPK1s, such as T. gondii, N. caninum, S. neurona, and 
Cryptosporidium spp (Table 3). Nonetheless, the optimal pharmacodynamics of treatment 
for Cryptosporidium spp., which are found in the greatest number in the proximal large 
bowel and reside on the tips of epithelial cells and project into the lumen of the gut, are 
expected to be quite different compared to T. gondii, N. caninum, and S. neurona, which 
cause systemic infection. Gut exposure is probably of primary importance for 
Cryptosporidium therapy, but broad systemic distribution is necessary for treatment of T. 
gondii, N. caninum, and S. neurona infections The apicomplexan organisms whose essential 
CDPKs have larger gatekeeper residues, such as threonine, are more difficult to inhibit 
selectively, yet the relatively poor choices of current therapeutics encourage us to continue 
development of BKIs for these pathogens. The encouraging results and long lasting plasma 
levels of BKIs give us optimism that BKIs can be developed to stop transmission of malaria.
Acknowledgments
This work was supported by the US National Institutes of Health (NICHHD R01HD080670 & NIAID 
R01AI111341, R01AI089441) and the USDA (2014-06183). This work was also supported by Swiss National 
Van Voorhis et al. Page 17
Exp Parasitol. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Science Foundation (grant No. 310030_165782) and in part by Career Development Award # BX002440 to J. Stone 
Doggett from the United States Department of Veterans Affairs Biomedical Laboratory Research and Development.
References
1. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the 
prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: 
recommendations from the Centers for Disease Control and Prevention, the National Institutes of 
Health, and the HIV Medicine Association of the Infectious Diseases Society of America.
2. Adams LG. Clinicopathological aspects of imidocarb dipropionate toxicity in horses. Res Vet Sci. 
1981; 31:54–61. [PubMed: 7313320] 
3. Arranz-Solís D, Aguado-Martínez A, Müller J, Regidor-Cerrillo J, Ortega-Mora LM, Hemphill A. 
Dose-dependent effects of experimental infection with the virulent Neospora caninum Nc-Spain7 
isolate in a pregnant mouse model. Vet Parasitol. 2015; 211:133–140. [PubMed: 26104964] 
4. Bishop AC, Buzko O, Shokat KM. Magic bullets for protein kinases. Trends Cell Biol. 2001; 
11:167–172. [PubMed: 11306297] 
5. Bishop AC, Shah K, Liu Y, Witucki L, Kung C, Shokat KM. Design of allele-specific inhibitors to 
probe protein kinase signaling. Curr Biol. 1998; 8:257–266. [PubMed: 9501066] 
6. Bishop AC, Shokat KM. Acquisition of inhibitor-sensitive protein kinases through protein design. 
Pharmacology & Therapeutics. 1999; 82:337–346. [PubMed: 10454210] 
7. Bishop AC, Ubersax JA, Petsch DT, Matheos DP, Gray NS, Blethrow J, Shimizu E, Tsien JZ, 
Schultz PG, Rose MD, Wood JL, Morgan DO, Shokat KM. A chemical switch for inhibitor-
sensitive alleles of any protein kinase. Nature. 2000; 407:395–401. [PubMed: 11014197] 
8. Bousema T, Drakeley C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium 
vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev. 2011; 24:377–
410. [PubMed: 21482730] 
9. Bousema T, Okell L, Shekalaghe S, Griffin JT, Omar S, Sawa P, Sutherland C, Sauerwein R, Ghani 
AC, Drakeley C. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular 
detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal 
drugs. Malaria Journal. 2010:9. [PubMed: 20064223] 
10. Brown WC, Norimine J, Knowles DP, Goff WL. Immune control of Babesia bovis infection. Vet 
Parasitol. 2006; 138:75–87. [PubMed: 16510249] 
11. Butler CM, Nijhof AM, van der Kolk JH, de Haseth OB, Taoufik A, Jongejan F, Houwers DJ. 
Repeated high dose imidocarb dipropionate treatment did not eliminate Babesia caballi from 
naturally infected horses as determined by PCR-reverse line blot hybridization. Vet Parasitol. 
2008; 151:320–322. [PubMed: 18160222] 
12. Carlson-Bremer DP, Gulland FM, Johnson CK, Colegrove KM, Van Bonn WG. Diagnosis and 
treatment of Sarcocystis neurona-induced myositis in a free-ranging California sea lion. J Am Vet 
Med Assoc. 2012; 240:324–328. [PubMed: 22256850] 
13. Castellanos-Gonzalez A, Sparks H, Nava S, Huang W, Zhang Z, Rivas K, Hulverson MA, Barrett 
LK, Ojo KK, Fan E, Van Voorhis WC, White AC Jr. A Novel Calcium-Dependent Kinase 
Inhibitor, Bumped Kinase Inhibitor 1517, Cures Cryptosporidiosis in Immunosuppressed Mice. J 
Infect Dis. 2016; 214:1850–1855. [PubMed: 27738055] 
14. Castellanos-Gonzalez A, White AC, Ojo KK, Vidadala RS, Zhang Z, Reid MC, Fox AM, Keyloun 
KR, Rivas K, Irani A, Dann SM, Fan E, Maly DJ, Van Voorhis WC. A novel calcium-dependent 
protein kinase inhibitor as a lead compound for treating cryptosporidiosis. J Infect Dis. 2013; 
208:1342–1348. [PubMed: 23878324] 
15. Chapman TM, Osborne SA, Bouloc N, Large JM, Wallace C, Birchall K, Ansell KH, Jones HM, 
Taylor D, Clough B, Green JL, Holder AA. Substituted imidazopyridazines are potent and 
selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1). 
Bioorg Med Chem Lett. 2013; 23:3064–3069. [PubMed: 23570789] 
16. Chapman TM, Osborne SA, Wallace C, Birchall K, Bouloc N, Jones HM, Ansell KH, Taylor DL, 
Clough B, Green JL, Holder AA. Optimization of an imidazopyridazine series of inhibitors of 
Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1). J Med Chem. 2014; 
57:3570–3587. [PubMed: 24689770] 
Van Voorhis et al. Page 18
Exp Parasitol. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
17. Cheadle MA, Tanhauser SM, Dame JB, Sellon DC, Hines M, Ginn PE, MacKay RJ, Greiner EC. 
The nine-banded armadillo (Dasypus novemcinctus) is an intermediate host for Sarcocystis 
neurona. Int J Parasitol. 2001; 31:330–335. [PubMed: 11306111] 
18. Cheadle MA, Yowell CA, Sellon DC, Hines M, Ginn PE, Marsh AE, Dame JB, Greiner EC. The 
striped skunk (Mephitis mephitis) is an intermediate host for Sarcocystis neurona. Int J Parasitol. 
2001; 31:843–849. [PubMed: 11403777] 
19. Coldham NG, Moore AS, Dave M, Graham PJ, Sivapathasundaram S, Lake BG, Sauer MJ. 
Imidocarb residues in edible bovine tissues and in vitro assessment of imidocarb metabolism and 
cytotoxicity. Drug Metab Dispos. 1995; 23:501–505. [PubMed: 7600919] 
20. Dannemann B, McCutchan JA, Israelski D, Antoniskis D, Leport C, Luft B, Nussbaum J, Clumeck 
N, Morlat P, Chiu J, et al. Treatment of toxoplasmic encephalitis in patients with AIDS. A 
randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. 
The California Collaborative Treatment Group. Ann Intern Med. 1992; 116:33–43. [PubMed: 
1727093] 
21. de Waal DT. Equine piroplasmosis: a review. Br Vet J. 1992; 148:6–14. [PubMed: 1551016] 
22. Delves M, Plouffe D, Scheurer C, Meister S, Wittlin S, Winzeler EA, Sinden RE, Leroy D. The 
activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study 
with human and rodent parasites. PLoS Med. 2012; 9:e1001169. [PubMed: 22363211] 
23. Dirikolu L, Karpiesiuk W, Lehner AF, Hughes C, Woods WE, Harkins JD, Boyles J, Atkinson A, 
Granstrom DE, Tobin T. New therapeutic approaches for equine protozoal myeloencephalitis: 
pharmacokinetics of diclazuril sodium salts in horses. Vet Ther. 2006; 7:52–63. 72. [PubMed: 
16598684] 
24. Diuk-Wasser MA, Vannier E, Krause PJ. Coinfection by Ixodes Tick-Borne Pathogens: Ecological, 
Epidemiological, and Clinical Consequences. Trends Parasitol. 2016; 32:30–42. [PubMed: 
26613664] 
25. Doggett JS, Ojo KK, Fan E, Maly DJ, Van Voorhis WC. Bumped kinase inhibitor 1294 treats 
established Toxoplasma gondii infection. Antimicrob Agents Chemother. 2014; 58:3547–3549. 
[PubMed: 24687502] 
26. Donnellan CM, Page PC, Nurton JP, van den Berg JS, Guthrie AJ. Comparison of glycopyrrolate 
and atropine in ameliorating the adverse effects of imidocarb dipropionate in horses. Equine Vet J. 
2013; 45:625–629. [PubMed: 23461655] 
27. Dubey JP, Dubey J. Review of Neospora caninum and neosporosis in animals. Korean J Parasitol. 
2003; 41:1–16. [PubMed: 12666725] 
28. Dubey JP, Howe DK, Furr M, Saville WJ, Marsh AE, Reed SM, Grigg ME. An update on 
Sarcocystis neurona infections in animals and equine protozoal myeloencephalitis (EPM). Vet 
Parasitol. 2015; 209:1–42. [PubMed: 25737052] 
29. Dubey JP, Lago EG, Gennari SM, Su C, Jones JL. Toxoplasmosis in humans and animals in Brazil: 
high prevalence, high burden of disease, and epidemiology. Parasitology. 2012; 139:1375–1424. 
[PubMed: 22776427] 
30. Dubey JP, Lindsay DS, Kerber CE, Kasai N, Pena HF, Gennari SM, Kwok OC, Shen SK, 
Rosenthal BM. First isolation of Sarcocystis neurona from the South American opossum, 
Didelphis albiventris, from Brazil. Vet Parasitol. 2001; 95:295–304. [PubMed: 11223209] 
31. Dubey JP, Rosypal AC, Rosenthal BM, Thomas NJ, Lindsay DS, Stanek JF, Reed SM, Saville WJ. 
Sarcocystis neurona infections in sea otter (Enhydra lutris): evidence for natural infections with 
sarcocysts and transmission of infection to opossums (Didelphis virginiana). J Parasitol. 2001; 
87:1387–1393. [PubMed: 11780826] 
32. Dubey JP, Saville WJ, Stanek JF, Lindsay DS, Rosenthal BM, Oglesbee MJ, Rosypal AC, Njoku 
CJ, Stich RW, Kwok OC, Shen SK, Hamir AN, Reed SM. Sarcocystis neurona infections in 
raccoons (Procyon lotor): evidence for natural infection with sarcocysts, transmission of infection 
to opossums (Didelphis virginiana), and experimental induction of neurologic disease in raccoons. 
Vet Parasitol. 2001; 100:117–129. [PubMed: 11698157] 
33. Dubey JP, Schares G, Ortega-Mora LM. Epidemiology and control of neosporosis and Neospora 
caninum. Clin Microbiol Rev. 2007; 20:323–367. [PubMed: 17428888] 
34. Fayer, R. Cryptosporidium and cryptosporidiosis. CRC Press; Boca Raton: 1997. 
Van Voorhis et al. Page 19
Exp Parasitol. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
35. Fenger CK, Granstrom DE, Langemeier JL, Stamper S, Donahue JM, Patterson JS, Gajadhar AA, 
Marteniuk JV, Xiaomin Z, Dubey JP. Identification of opossums (Didelphis virginiana) as the 
putative definitive host of Sarcocystis neurona. J Parasitol. 1995; 81:916–919. [PubMed: 8544064] 
36. Frerichs WM, Allen PC, Holbrook AA. Equine piroplasmosis (Babesia equi): therapeutic trials of 
imidocarb dihydrochloride in horses and donkeys. Vet Rec. 1973; 93:73–75. [PubMed: 4748680] 
37. Furr M, Kennedy T, MacKay R, Reed S, Andrews F, Bernard B, Bain F, Byars D. Efficacy of 
ponazuril 15% oral paste as a treatment for equine protozoal myeloencephalitis. Vet Ther. 2001; 
2:215–222. [PubMed: 19746664] 
38. Gohil S, Herrmann S, Günther S, Cooke BM. Bovine babesiosis in the 21st century: advances in 
biology and functional genomics. Int J Parasitol. 2013; 43:125–132. [PubMed: 23068911] 
39. Gonzalez-Warleta M, Castro-Hermida JA, Regidor-Cerrillo J, Benavides J, Alvarez-Garcia G, 
Fuertes M, Ortega-Mora LM, Mezo M. Neospora caninum infection as a cause of reproductive 
failure in a sheep flock. Vet Res. 2014; 45:88. [PubMed: 25158756] 
40. Grause JF, Ueti MW, Nelson JT, Knowles DP, Kappmeyer LS, Bunn TO. Efficacy of imidocarb 
dipropionate in eliminating Theileria equi from experimentally infected horses. Vet J. 2013; 
196:541–546. [PubMed: 23199699] 
41. Green JL, Moon RW, Whalley D, Bowyer PW, Wallace C, Rochani A, Nageshan RK, Howell SA, 
Grainger M, Jones HM, Ansell KH, Chapman TM, Taylor DL, Osborne SA, Baker DA, Tatu U, 
Holder AA. Imidazopyridazine Inhibitors of Plasmodium falciparum Calcium-Dependent Protein 
Kinase 1 Also Target Cyclic GMP-Dependent Protein Kinase and Heat Shock Protein 90 To Kill 
the Parasite at Different Stages of Intracellular Development. Antimicrob Agents Chemother. 
2016; 60:1464–1475.
42. Hackstein JH, Mackenstedt U, Mehlhorn H, Meijerink JP, Schubert H, Leunissen JA. Parasitic 
apicomplexans harbor a chlorophyll a-D1 complex, the potential target for therapeutic triazines. 
Parasitol Res. 1995; 81:207–216. [PubMed: 7770426] 
43. Harrell M, Carvounis PE. Current treatment of toxoplasma retinochoroiditis: an evidence-based 
review. J Ophthalmol. 2014; 2014:273506. [PubMed: 25197557] 
44. Hemphill A, Aguado-Martínez A, Müller J. Approaches for the vaccination and treatment of 
Neospora caninum infections in mice and ruminant models. Parasitology. 2016; 143:245–259. 
[PubMed: 26626124] 
45. Hines SA, Ramsay JD, Kappmeyer LS, Lau AO, Ojo KK, Van Voorhis WC, Knowles DP, Mealey 
RH. Theileria equi isolates vary in susceptibility to imidocarb dipropionate but demonstrate 
uniform in vitro susceptibility to a bumped kinase inhibitor. Parasit Vectors. 2015; 8:33. [PubMed: 
25600252] 
46. Homer MJ, Aguilar-Delfin I, Telford SR, Krause PJ, Persing DH. Babesiosis. Clin Microbiol Rev. 
2000; 13:451–469. [PubMed: 10885987] 
47. Howe DK, MacKay RJ, Reed SM. Equine protozoal myeloencephalitis. Vet Clin North Am Equine 
Pract. 2014; 30:659–675. [PubMed: 25441115] 
48. Huang W, Ojo KK, Zhang Z, Rivas K, Vidadala RS, Scheele S, DeRocher AE, Choi R, Hulverson 
MA, Barrett LK, Bruzual I, Siddaramaiah LK, Kerchner KM, Kurnick MD, Freiberg GM, Kempf 
D, Hol WG, Merritt EA, Neckermann G, de Hostos EL, Isoherranen N, Maly DJ, Parsons M, 
Doggett JS, Van Voorhis WC, Fan E. SAR Studies of 5-Aminopyrazole-4-carboxamide Analogues 
as Potent and Selective Inhibitors of Toxoplasma gondii CDPK1. ACS Med Chem Lett. 2015; 
6:1184–1189. [PubMed: 26693272] 
49. Imboden M, Schaefer DA, Bremel RD, Homan EJ, Riggs MW. Antibody fusions reduce onset of 
experimental Cryptosporidium parvum infection in calves. Vet Parasitol. 2012; 188:41–47. 
[PubMed: 22455725] 
50. Johnson SM, Murphy RC, Geiger JA, DeRocher AE, Zhang Z, Ojo KK, Larson ET, Perera BG, 
Dale EJ, He P, Reid MC, Fox AM, Mueller NR, Merritt EA, Fan E, Parsons M, Van Voorhis WC, 
Maly DJ. Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) 
inhibitors with potent anti-toxoplasma activity. J Med Chem. 2012; 55:2416–2426. [PubMed: 
22320388] 
Van Voorhis et al. Page 20
Exp Parasitol. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
51. Jongwutiwes S, Putaporntip C, Iwasaki T, Sata T, Kanbara H. Naturally acquired Plasmodium 
knowlesi malaria in human, Thailand. Emerg Infect Dis. 2004; 10:2211–2213. [PubMed: 
15663864] 
52. Katlama C, De Wit S, O'Doherty E, Van Glabeke M, Clumeck N. Pyrimethamine-clindamycin vs. 
pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in 
patients with AIDS. Clin Infect Dis. 1996; 22:268–275. [PubMed: 8838183] 
53. Keyloun KR, Reid MC, Choi R, Song Y, Fox AM, Hillesland HK, Zhang Z, Vidadala R, Merritt 
EA, Lau AO, Maly DJ, Fan E, Barrett LK, VAN Voorhis WC, Ojo KK. The gatekeeper residue and 
beyond: homologous calcium-dependent protein kinases as drug development targets for 
veterinarian Apicomplexa parasites. Parasitology. 2014; 141:1499–1509. [PubMed: 24927073] 
54. Khan A, Jordan C, Muccioli C, Vallochi AL, Rizzo LV, Belfort R Jr, Vitor RW, Silveira C, Sibley 
LD. Genetic divergence of Toxoplasma gondii strains associated with ocular toxoplasmosis, 
Brazil. Emerg Infect Dis. 2006; 12:942–949. [PubMed: 16707050] 
55. Knapp KL, Rice NA. Human Coinfection with Borrelia burgdorferi and Babesia microti in the 
United States. J Parasitol Res. 2015; 2015:587131. [PubMed: 26697208] 
56. Knowles DP. Control of Babesia equi parasitemia. Parasitol Today. 1996; 12:195–198. [PubMed: 
15275213] 
57. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, Wu Y, Sow SO, 
Sur D, Breiman RF, Faruque AS, Zaidi AK, Saha D, Alonso PL, Tamboura B, Sanogo D, 
Onwuchekwa U, Manna B, Ramamurthy T, Kanungo S, Ochieng JB, Omore R, Oundo JO, 
Hossain A, Das SK, Ahmed S, Qureshi S, Quadri F, Adegbola RA, Antonio M, Hossain MJ, 
Akinsola A, Mandomando I, Nhampossa T, Acácio S, Biswas K, O'Reilly CE, Mintz ED, Berkeley 
LY, Muhsen K, Sommerfelt H, Robins-Browne RM, Levine MM. Burden and aetiology of 
diarrhoeal disease in infants and young children in developing countries (the Global Enteric 
Multicenter Study, GEMS): a prospective, case-control study. Lancet. 2013; 382:209–222. 
[PubMed: 23680352] 
58. Kumar S, Gupta AK, Pal Y, Dwivedi SK. In-vivo therapeutic efficacy trial with artemisinin 
derivative, buparvaquone and imidocarb dipropionate against Babesia equi infection in donkeys. J 
Vet Med Sci. 2003; 65:1171–1177. [PubMed: 14665744] 
59. Kumar S, Kumar R, Sugimoto C. A perspective on Theileria equi infections in donkeys. Jpn J Vet 
Res. 2009; 56:171–180. [PubMed: 19358444] 
60. Kuttler KL, Zaugg JL, Gipson CA. Imidocarb and parvaquone in the treatment of piroplasmosis 
(Babesia equi) in equids. Am J Vet Res. 1987; 48:1613–1616. [PubMed: 3434908] 
61. Lapointe JM, Duignan PJ, Marsh AE, Gulland FM, Barr BC, Naydan DK, King DP, Farman CA, 
Huntingdon KA, Lowenstine LJ. Meningoencephalitis due to a Sarcocystis neurona-like protozoan 
in Pacific harbor seals (Phoca vitulina richardsi). J Parasitol. 1998; 84:1184–1189. [PubMed: 
9920311] 
62. Larson ET, Ojo KK, Murphy RC, Johnson SM, Zhang Z, Kim JE, Leibly DJ, Fox AM, Reid MC, 
Dale EJ, Perera BG, Kim J, Hewitt SN, Hol WG, Verlinde CL, Fan E, Van Voorhis WC, Maly DJ, 
Merritt EA. Multiple determinants for selective inhibition of apicomplexan calcium–dependent 
protein kinase CDPK1. J Med Chem. 2012; 55:2803–2810. [PubMed: 22369268] 
63. Lindsay DS, Thomas NJ, Rosypal AC, Dubey JP. Dual Sarcocystis neurona and Toxoplasma gondii 
infection in a Northern sea otter from Washington state, USA. Vet Parasitol. 2001; 97:319–327. 
[PubMed: 11390085] 
64. Liu Y, Bishop A, Witucki L, Kraybill B, Shimizu E, Tsien J, Ubersax J, Blethrow J, Morgan DO, 
Shokat KM. Structural basis for selective inhibition of Src family kinases by PP1. Chem Biol. 
1999; 6:671–678. [PubMed: 10467133] 
65. Lourido S, Shuman J, Zhang C, Shokat KM, Hui R, Sibley LD. Calcium-dependent protein kinase 
1 is an essential regulator of exocytosis in Toxoplasma. Nature. 2010; 465:359–362. [PubMed: 
20485436] 
66. Lourido S, Tang K, Sibley LD. Distinct signalling pathways control Toxoplasma egress and host–
cell invasion. EMBO J. 2012; 31:4524–4534. [PubMed: 23149386] 
Van Voorhis et al. Page 21
Exp Parasitol. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
67. Lourido S, Zhang C, Lopez MS, Tang K, Barks J, Wang Q, Wildman SA, Shokat KM, Sibley LD. 
Optimizing small molecule inhibitors of calcium-dependent protein kinase 1 to prevent infection 
by Toxoplasma gondii. J Med Chem. 2013; 56:3068–3077. [PubMed: 23470217] 
68. Mackay RJ, Tanhauser ST, Gillis KD, Mayhew IG, Kennedy TJ. Effect of intermittent oral 
administration of ponazuril on experimental Sarcocystis neurona infection of horses. Am J Vet 
Res. 2008; 69:396–402. [PubMed: 18312139] 
69. Martino R, Bretagne S, Einsele H, Maertens J, Ullmann AJ, Parody R, Schumacher U, Pautas C, 
Theunissen K, Schindel C, Munoz C, Margall N, Cordonnier C, Marrow T. Infectious Disease 
Working Party of the European Group for B. Early detection of Toxoplasma infection by 
molecular monitoring of Toxoplasma gondii in peripheral blood samples after allogeneic stem cell 
transplantation. Clin Infect Dis. 2005; 40:67–78. [PubMed: 15614694] 
70. McLeod R, Boyer K, Karrison T, Kasza K, Swisher C, Roizen N, Jalbrzikowski J, Remington J, 
Heydemann P, Noble AG, Mets M, Holfels E, Withers S, Latkany P, Meier P. Toxoplasmosis Study 
G. Outcome of treatment for congenital toxoplasmosis, 1981–2004: the National Collaborative 
Chicago-Based, Congenital Toxoplasmosis Study. Clin Infect Dis. 2006; 42:1383–1394. [PubMed: 
16619149] 
71. Meyer C, Guthrie AJ, Stevens KB. Clinical and clinicopathological changes in 6 healthy ponies 
following intramuscular administration of multiple doses of imidocarb dipropionate. J S Afr Vet 
Assoc. 2005; 76:26–32. [PubMed: 15900897] 
72. Miller MA, Conrad PA, Harris M, Hatfield B, Langlois G, Jessup DA, Magargal SL, Packham AE, 
Toy-Choutka S, Melli AC, Murray MA, Gulland FM, Grigg ME. A protozoal-associated epizootic 
impacting marine wildlife: mass-mortality of southern sea otters (Enhydra lutris nereis) due to 
Sarcocystis neurona infection. Vet Parasitol. 2010; 172:183–194. [PubMed: 20615616] 
73. Moine E, Denevault-Sabourin C, Debierre-Grockiego F, Silpa L, Gorgette O, Barale JC, Jacquiet P, 
Brossier F, Gueiffier A, Dimier-Poisson I, Enguehard-Gueiffier C. A small-molecule cell-based 
screen led to the identification of biphenylimidazoazines with highly potent and broad-spectrum 
anti-apicomplexan activity. Eur J Med Chem. 2015; 89:386–400. [PubMed: 25462254] 
74. Moine E, Dimier-Poisson I, Enguehard-Gueiffier C, Loge C, Penichon M, Moire N, Delehouze C, 
Foll-Josselin B, Ruchaud S, Bach S, Gueiffier A, Debierre-Grockiego F, Denevault-Sabourin C. 
Development of new highly potent imidazo[1,2-b]pyridazines targeting Toxoplasma gondii 
calcium-dependent protein kinase 1. Eur J Med Chem. 2015; 105:80–105. [PubMed: 26479029] 
75. Monney T, Hemphill A. Vaccines against neosporosis: what can we learn from the past studies? 
Exp Parasitol. 2014; 140:52–70. [PubMed: 24602874] 
76. Moreno B, Collantes-Fernandez E, Villa A, Navarro A, Regidor-Cerrillo J, Ortega-Mora LM. 
Occurrence of Neospora caninum and Toxoplasma gondii infections in ovine and caprine 
abortions. Vet Parasitol. 2012; 187:312–318. [PubMed: 22260901] 
77. Murphy RC, Ojo KK, Larson ET, Castellanos-Gonzalez A, Perera BG, Keyloun KR, Kim JE, 
Bhandari JG, Muller NR, Verlinde CL, White AC Jr, Merritt EA, Van Voorhis WC, Maly DJ. 
Discovery of Potent and Selective Inhibitors of Calcium-Dependent Protein Kinase 1 (CDPK1) 
from C. parvum and T. gondii. ACS Med Chem Lett. 2010; 1:331–335. [PubMed: 21116453] 
78. Nagamune K, Sibley LD. Comparative genomic and phylogenetic analyses of calcium ATPases 
and calcium-regulated proteins in the apicomplexa. Mol Biol Evol. 2006; 23:1613–1627. 
[PubMed: 16751258] 
79. Ojo KK, Dangoudoubiyam S, Verma SK, Scheele S, DeRocher AE, Yeargan M, Choi R, Smith 
RR, Rivas KL, Hulverson MA, Barrett LK, Fan E, Maly DJ, Parsons M, Dubey JP, Howe DK, Van 
Voorhis WC. Selective Inhibition of Sarcocystis neurona Calcium-Dependent Protein Kinase 1 for 
Equine Protozoal Myeloencephalitis Therapy. International Journal for Parasitology. 2016 in press. 
80. Ojo KK, Eastman RT, Vidadala R, Zhang Z, Rivas KL, Choi R, Lutz JD, Reid MC, Fox AM, 
Hulverson MA, Kennedy M, Isoherranen N, Kim LM, Comess KM, Kempf DJ, Verlinde CL, Su 
XZ, Kappe SH, Maly DJ, Fan E, Van Voorhis WC. A Specific Inhibitor of PfCDPK4 Blocks 
Malaria Transmission: Chemical-genetic Validation. J Infect Dis. 2014; 209:275–284. [PubMed: 
24123773] 
81. Ojo KK, Larson ET, Keyloun KR, Castaneda LJ, Derocher AE, Inampudi KK, Kim JE, Arakaki 
TL, Murphy RC, Zhang L, Napuli AJ, Maly DJ, Verlinde CL, Buckner FS, Parsons M, Hol WG, 
Van Voorhis et al. Page 22
Exp Parasitol. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Merritt EA, Van Voorhis WC. Toxoplasma gondii calcium-dependent protein kinase 1 is a target 
for selective kinase inhibitors. Nat Struct Mol Biol. 2010; 17:602–607. [PubMed: 20436472] 
82. Ojo KK, Pfander C, Mueller NR, Burstroem C, Larson ET, Bryan CM, Fox AM, Reid MC, 
Johnson SM, Murphy RC, Kennedy M, Mann H, Leibly DJ, Hewitt SN, Verlinde CL, Kappe S, 
Merritt EA, Maly DJ, Billker O, Van Voorhis WC. Transmission of malaria to mosquitoes blocked 
by bumped kinase inhibitors. J Clin Invest. 2012; 122:2301–2305. [PubMed: 22565309] 
83. Ojo KK, Reid MC, Kallur Siddaramaiah L, Muller J, Winzer P, Zhang Z, Keyloun KR, Vidadala 
RS, Merritt EA, Hol WG, Maly DJ, Fan E, Van Voorhis WC, Hemphill A. Neospora caninum 
calcium-dependent protein kinase 1 is an effective drug target for neosporosis therapy. PLoS One. 
2014; 9:e92929. [PubMed: 24681759] 
84. Pantenburg B, Cabada MM, White AC Jr. Treatment of cryptosporidiosis. Expert Rev Anti Infect 
Ther. 2009; 7:385–391. [PubMed: 19400754] 
85. Pedersen PJ, Thomsen KB, Olander ER, Hauser F, Tejada MeL, Poulsen KL, Grubb S, Buhl R, 
Calloe K, Klaerke DA. Molecular Cloning and Functional Expression of the Equine K+ Channel 
KV11.1 (Ether à Go-Go-Related/KCNH2 Gene) and the Regulatory Subunit KCNE2 from Equine 
Myocardium. PLoS One. 2015; 10:e0138320. [PubMed: 26376488] 
86. Pedroni MJ, Vidadala RS, Choi R, Keyloun KR, Reid MC, Murphy RC, Barrett LK, Van Voorhis 
WC, Maly DJ, Ojo KK, Lau AO. Bumped kinase inhibitor prohibits egression in Babesia bovis. 
Vet Parasitol. 2016; 215:22–28. [PubMed: 26790733] 
87. Porter SB, Sande MA. Toxoplasmosis of the central nervous system in the acquired 
immunodeficiency syndrome. N Engl J Med. 1992; 327:1643–1648. [PubMed: 1359410] 
88. Rabaud C, May T, Amiel C, Katlama C, Leport C, Ambroise-Thomas P, Canton P. Extracerebral 
toxoplasmosis in patients infected with HIV. A French National Survey. Medicine (Baltimore). 
1994; 73:306–314. [PubMed: 7984082] 
89. Reed SM, Furr M, Howe DK, Johnson AL, MacKay RJ, Morrow JK, Pusterla N, Witonsky S. 
Equine Protozoal Myeloencephalitis: An Updated Consensus Statement with a Focus on Parasite 
Biology, Diagnosis, Treatment, and Prevention. J Vet Intern Med. 2016; 30:491–502. [PubMed: 
26857902] 
90. Reichel MP, Alejandra Ayanegui-Alcérreca M, Gondim LF, Ellis JT. What is the global economic 
impact of Neospora caninum in cattle - the billion dollar question. Int J Parasitol. 2013; 43:133–
142. [PubMed: 23246675] 
91. Rosonke BJ, Brown SR, Tornquist SJ, Snyder SP, Garner MM, Blythe LL. Encephalomyelitis 
associated with a Sarcocystis neurona-like organism in a sea otter. J Am Vet Med Assoc. 1999; 
215:1839–1842. 1807. [PubMed: 10613219] 
92. Schaefer DA, Auerbach-Dixon BA, Riggs MW. Characterization and formulation of multiple 
epitope-specific neutralizing monoclonal antibodies for passive immunization against 
cryptosporidiosis. Infect Immun. 2000; 68:2608–2616. [PubMed: 10768951] 
93. Schaefer DA, Betzer DP, Smith KD, Millman ZG, Michalski HC, Menchaca SE, Zambriski JA, 
Ojo KK, Hulverson MA, Arnold SL, Rivas KL, Vidadala RS, Huang W, Barrett LK, Maly DJ, Fan 
E, Van Voorhis WC, Riggs MW. Novel Bumped Kinase Inhibitors Are Safe and Effective 
Therapeutics in the Calf Clinical Model for Cryptosporidiosis. J Infect Dis. 2016; 214:1856–1864. 
[PubMed: 27923949] 
94. Schneider P, Bousema T, Omar S, Gouagna L, Sawa P, Schallig H, Sauerwein R. (Sub)microscopic 
Plasmodium falciparum gametocytaemia in Kenyan children after treatment with sulphadoxine-
pyrimethamine monotherapy or in combination with artesunate. Int J Parasitol. 2006; 36:403–408. 
[PubMed: 16500657] 
95. Scoles GA, Hutcheson HJ, Schlater JL, Hennager SG, Pelzel AM, Knowles DP. Equine 
piroplasmosis associated with Amblyomma cajennense Ticks, Texas, USA. Emerg Infect Dis. 
2011; 17:1903–1905. [PubMed: 22000367] 
96. Short MA, Clark CK, Harvey JW, Wenzlow N, Hawkins IK, Allred DR, Knowles DP, Corn JL, 
Grause JF, Hennager SG, Kitchen DL, Traub-Dargatz JL. Outbreak of equine piroplasmosis in 
Florida. J Am Vet Med Assoc. 2012; 240:588–595. [PubMed: 22332629] 
Van Voorhis et al. Page 23
Exp Parasitol. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
97. Sugi T, Kawazu S, Horimoto T, Kato K. A single mutation in the gatekeeper residue in 
TgMAPKL-1 restores the inhibitory effect of a bumped kinase inhibitor on the cell cycle. Int J 
Parasitol Drugs Drug Resist. 2015; 5:1–8. [PubMed: 25941623] 
98. Taylor SM, Kenny J, Mallon T. The effect of multiple rapid passage on strains of Babesia 
divergens: a comparison of the clinical effects on juvenile and adult cattle of passaged and 
irradiated parasites. J Comp Pathol. 1983; 93:391–396. [PubMed: 6886085] 
99. Tecles F, Cerón JJ. Determination of whole blood cholinesterase in different animal species using 
specific substrates. Res Vet Sci. 2001; 70:233–238. [PubMed: 11676619] 
100. Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int J 
Parasitol. 2000; 30:1217–1258. [PubMed: 11113252] 
101. Tran TM, Li S, Doumbo S, Doumtabe D, Huang CY, Dia S, Bathily A, Sangala J, Kone Y, Traore 
A, Niangaly M, Dara C, Kayentao K, Ongoiba A, Doumbo OK, Traore B, Crompton PD. An 
intensive longitudinal cohort study of Malian children and adults reveals no evidence of acquired 
immunity to Plasmodium falciparum infection. Clin Infect Dis. 2013; 57:40–47. [PubMed: 
23487390] 
102. Ueti MW, Mealey RH, Kappmeyer LS, White SN, Kumpula-McWhirter N, Pelzel AM, Grause JF, 
Bunn TO, Schwartz A, Traub-Dargatz JL, Hendrickson A, Espy B, Guthrie AJ, Fowler WK, 
Knowles DP. Re-emergence of the apicomplexan Theileria equi in the United States: elimination 
of persistent infection and transmission risk. PLoS One. 2012; 7:e44713. [PubMed: 22970295] 
103. United States. Animal and Plant Health Inspection Service. Equine piroplasmosis, APHIS 
factsheet. U.S. Dept. of Agriculture, Animal and Plant Health Inspection Service; Riverdale, Md: 
2008. p. 2unnumbered pages
104. Vannier EG, Diuk-Wasser MA, Ben Mamoun C, Krause PJ. Babesiosis. Infect Dis Clin North 
Am. 2015; 29:357–370. [PubMed: 25999229] 
105. Vidadala RS, Ojo KK, Johnson SM, Zhang Z, Leonard SE, Mitra A, Choi R, Reid MC, Keyloun 
KR, Fox AM, Kennedy M, Silver-Brace T, Hume JC, Kappe S, Verlinde CL, Fan E, Merritt EA, 
Van Voorhis WC, Maly DJ. Development of potent and selective Plasmodium falciparum 
calcium-dependent protein kinase 4 (PfCDPK4) inhibitors that block the transmission of malaria 
to mosquitoes. Eur J Med Chem. 2014; 74:562–573. [PubMed: 24531197] 
106. Vidadala RS, Rivas KL, Ojo KK, Hulverson MA, Zambriski JA, Bruzual I, Schultz TL, Huang W, 
Zhang Z, Scheele S, DeRocher AE, Choi R, Barrett LK, Siddaramaiah LK, Hol WG, Fan E, 
Merritt EA, Parsons M, Freiberg G, Marsh K, Kempf DJ, Carruthers VB, Isoherranen N, Doggett 
JS, Van Voorhis WC, Maly DJ. Development of an Orally Available and Central Nervous System 
(CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor 
with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of 
Toxoplasmosis. J Med Chem. 2016; 59:6531–6546. [PubMed: 27309760] 
107. Wellems TE, Hayton K, Fairhurst RM. The impact of malaria parasitism: from corpuscles to 
communities. J Clin Invest. 2009; 119:2496–2505. [PubMed: 19729847] 
108. Wernimont AK, Artz JD, Finerty P, Lin YH, Amani M, Allali-Hassani A, Senisterra G, Vedadi M, 
Tempel W, Mackenzie F, Chau I, Lourido S, Sibley LD, Hui R. Structures of apicomplexan 
calcium-dependent protein kinases reveal mechanism of activation by calcium. Nat Struct Mol 
Biol. 2010; 17:596–601. [PubMed: 20436473] 
109. Wilairatana P, Krudsood S, Tangpukdee N. Appropriate time for primaquine treatment to reduce 
Plasmodium falciparum transmission in hypoendemic areas. Korean J Parasitol. 2010; 48:179–
182. [PubMed: 20585538] 
110. Winzer P, Muller J, Aguado-Martinez A, Rahman M, Balmer V, Manser V, Ortega-Mora LM, Ojo 
KK, Fan E, Maly DJ, Van Voorhis WC, Hemphill A. In Vitro and In Vivo Effects of the Bumped 
Kinase Inhibitor 1294 in the Related Cyst-Forming Apicomplexans Toxoplasma gondii and 
Neospora caninum. Antimicrob Agents Chemother. 2015; 59:6361–6374. [PubMed: 26248379] 
111. World Health Organization. World Malaria Report 2014. World Health Organization; Geneva, 
Switzerland: 2014. 
112. Zhang C, Kenski DM, Paulson JL, Bonshtien A, Sessa G, Cross JV, Templeton DJ, Shokat KM. A 
second-site suppressor strategy for chemical genetic analysis of diverse protein kinases. Nat 
Methods. 2005; 2:435–441. [PubMed: 15908922] 
Van Voorhis et al. Page 24
Exp Parasitol. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
113. Zhang Z, Ojo KK, Johnson SM, Larson ET, He P, Geiger JA, Castellanos-Gonzalez A, White AC, 
Parsons M, Merritt EA, Maly DJ, Verlinde CL, Van Voorhis WC, Fan E. Benzoylbenzimidazole-
based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-
dependent protein kinase-1. Bioorg Med Chem Lett. 2012; 22:5264–5267. [PubMed: 22795629] 
114. Zhang Z, Ojo KK, Vidadala R, Huang W, Geiger JA, Scheele S, Choi R, Reid MC, Keyloun KR, 
Rivas K, Siddaramaiah LK, Comess KM, Robinson KP, Merta PJ, Kifle L, Hol WG, Parsons M, 
Merritt EA, Maly DJ, Verlinde CL, Van Voorhis WC, Fan E. Potent and selective inhibitors of 
CDPK1 from T. gondii and C. parvum based on a 5-aminopyrazole-4-carboxamide scaffold. ACS 
Med Chem Lett. 2014; 5:40–44. [PubMed: 24494061] 
115. Zuccotto F, Ardini E, Casale E, Angiolini M. Through the "gatekeeper door": exploiting the active 
kinase conformation. J Med Chem. 2010; 53:2681–2694. [PubMed: 20000735] 
Van Voorhis et al. Page 25
Exp Parasitol. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Highlights
• Many apicomplexan calcium dependent protein kinases (CDPKs) are 
validated drug targets
• These CDPKs have atypically small gatekeeper residues and are inhibited by 
bumped kinase inhibitors (BKIs)
• Highly selective ATP-competitive BKIs inhibit growth of many apicomplexan 
parasites at concentrations non-toxic to mammalian cells and some have 
demonstrated proof-of- concept therapy in animal infection models
• BKIs have potential as therapeutics for diseases caused by apicomplexan 
pathogens
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Fig. 1. BKIs core scaffold and orientation with enzymes ATP binding sites
(a) Pyrazolopyrimidines (PP) and alternative 5-aminopyrazole-4-carboxamide (AC) scaffold 
chemical backbone for CDPK inhibitors. (b) Typical protein kinase active site. The volume 
accessible for ATP binding, indicated by the thick blue line, is limited by the presence of a 
large gatekeeper residue, in this case phenylalanine 103 of human CDK9. (c) Active site of 
T. gondii CDPK1 with AC scaffold BKI-1517. The large R1 substituent occupies a 
hydrophobic region made accessible by the absence of sidechain atoms in the glycine 
gatekeeper residue. (d) Active site of N. caninum CDPK1 with PP scaffold BKI-1294. In 
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addition to the large R1 group, this inhibitor contains a large R2 group that extends deeper 
into the ribose pocket. The three crystal structures shown are 3BLQ, 4ONA, and 4MX9.
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Fig. 2. Imidazopyridazines and benzoylbenzimidazoles
are two other chemical scaffolds previously used as backbone for development of BKIs to 
target apicomplexan parasite enzymes.
Van Voorhis et al. Page 29
Exp Parasitol. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 3. Chemical structures
Chemical structures of lead bumped kinase inhibitors with demonstrated activities against 
apicomplexan calcium-dependent protein kinase enzymes and parasites growth and 
proliferation.
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Fig. 4. BKI-1294 induces the formation of multinucleated parasite complexes in N.caninum 
infected cells
A: TEM showing a parasitophorous vacuole containing numerous N. caninum tachyzoites 
cultured in the absence of BKI-1294. B. N. caninum tachyzoites were allowed to invade the 
host cells and were then treated with BKI-1294 (2.5μM) for 6 days. Note the formation of 
multinucleated parasites, still enclosed within a vacuole. n = parasite nucleus; hn = host cell 
nucleus. Bars = 1 μm
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